Ftse Mib
34.236,40
0,15%
DAX
19.989,00
0,40%
S&P 500
5.904,27
0,38%
NASDAQ
19.507,11
1,02%
Bitcoin
96.534,14
2,27%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immuneering Corporation (IMRX) Immuneering Corporation (IMRX) Notizie

IMRX

Immuneering (IMRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMRX
DataOraFonteTitoloSimboloCompagnia
19/12/202414:00GlobeNewswire Inc.Immuneering Launches Pancreatic Cancer Advisory BoardNASDAQ:IMRXImmuneering Corporation
17/12/202414:00GlobeNewswire Inc.Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025NASDAQ:IMRXImmuneering Corporation
12/12/202414:00GlobeNewswire Inc.Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced MelanomaNASDAQ:IMRXImmuneering Corporation
27/11/202414:00GlobeNewswire Inc.Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
13/11/202422:05GlobeNewswire Inc.Immuneering Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
13/11/202422:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
15/10/202419:00AllPennyStocks.comBiotech Shares Rip Following FDA Designation AnnouncementNASDAQ:IMRXImmuneering Corporation
15/10/202414:00GlobeNewswire Inc.Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
02/10/202422:11Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:IMRXImmuneering Corporation
17/09/202422:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
13/09/202415:40AllPennyStocks.comBiotech Surges Premarket Following Positive Phase 2a ObservationsNASDAQ:IMRXImmuneering Corporation
12/09/202422:05GlobeNewswire Inc.Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer PatientsNASDAQ:IMRXImmuneering Corporation
29/08/202414:00GlobeNewswire Inc.Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
06/08/202422:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMRXImmuneering Corporation
06/08/202422:05GlobeNewswire Inc.Immuneering Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
31/07/202422:05GlobeNewswire Inc.Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
29/05/202422:05GlobeNewswire Inc.Immuneering to Present at the Jefferies Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
07/05/202422:05GlobeNewswire Inc.Immuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
06/05/202422:30GlobeNewswire Inc.Immuneering Recognizes Melanoma Awareness MonthNASDAQ:IMRXImmuneering Corporation
09/04/202418:00GlobeNewswire Inc.IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsNASDAQ:IMRXImmuneering Corporation
03/04/202422:05GlobeNewswire Inc.Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
27/03/202413:00GlobeNewswire Inc.Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsNASDAQ:IMRXImmuneering Corporation
14/03/202412:00GlobeNewswire Inc.Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
12/03/202413:00GlobeNewswire Inc.Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of DirectorsNASDAQ:IMRXImmuneering Corporation
11/03/202413:00GlobeNewswire Inc.Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
05/03/202423:00GlobeNewswire Inc.Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024NASDAQ:IMRXImmuneering Corporation
04/03/202414:00GlobeNewswire Inc.Immuneering to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:IMRXImmuneering Corporation
01/03/202414:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMRXImmuneering Corporation
01/03/202414:00GlobeNewswire Inc.Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
20/02/202414:00GlobeNewswire Inc.Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMRX

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BPE
Bper Banca
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
SPM
Saipem
BIT
RACE
Ferrari NV
BIT
STMMI
ST Microelectronics
BIT
IVG
Iveco Group NV
BIT
BAMI
Banco BPM
BIT
MONC
Moncler
BIT
TIT
Telecom Italia
BIT
SRG
Snam
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network